2334 GMT - Wider adoption of Pro Medicus's medical-imaging tech looks inevitable to its bulls at Goldman Sachs. Calling Pro Medicus one of Australia's best global growth companies, GS analysts write in a note that they expect a strong increase in the cadence and value of contract wins over time. Adoption is a matter of when, not if, they reckon. The analysts think that there is potential for material upside from outsized contracts worth more than A$100 million, but they acknowledge that visibility here is limited in terms of both size and timing. GS lifts its target price 26% to A$278.00 and keeps a buy rating on the stock. Shares are up 3.7% at A$256.29. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
December 11, 2024 18:34 ET (23:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。